ReviewiScience2025
Dual-specificity protein phosphatase 1: A potential therapeutic target in cancer.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- DUSP family phosphatases in cell signaling, inflammation, and chronic diseases.Journal of biomedical science · 2026Review
- The immunogenetic basis of ovarian apoptosis: from TNF-α polymorphisms and signaling pathways to glucocorticoid-mediated rescue.Journal of ovarian research · 2026Review
- Chemotherapy-Induced Oral Mucosal Injury Is Defined by p53 Activation, Cell Cycle Arrest and Diverse Epithelial Progenitor Dynamics.bioRxiv : the preprint server for biology · 2026Article
- Characterization of Oncogenic and Immunogenic Profiling in Patients with Breast Cancer Tumors After Radiation Therapy.International journal of molecular sciences · 2026Article
- DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential.Current oncology (Toronto, Ont.) · 2026Review
- Discovery of Two Novel Pyrazole Derivatives as Anticancer Agents Targeting Tubulin Polymerization and MAPK Signaling Pathways.Oncology research · 2026Article
- Integrative multi-cohort analysis of DNA methylation profiles for pancreatic ductal adenocarcinoma biomarker discovery and prognosis.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dual-specificity protein phosphatase 1 (DUSP1), also known as MAP kinase phosphatase 1 (MKP1), is a key member of the dual-specificity phosphatase family that dephosphorylates both threonine and tyrosine residues on mitogen-activated protein kinases (MAPKs). By inactivating critical MAPK signaling pathways, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, DUSP1 serves as a pivotal regulator of diverse cellular processes such as proliferation, differentiation, apoptosis, autophagy, and stress responses. Emerging evidence highlights its context-dependent roles in cancer progression, where DUSP1 can function either as a tumor suppressor or promoter depending on the tumor type, stage, and tumor microenvironment (TME). Aberrant DUSP1 regulation is implicated in modulating cancer cell resistance to chemotherapy and radiotherapy, as well as facilitating immune evasion within the TME. This review provides a comprehensive overview of DUSP1, including molecular, structural, and regulatory mechanisms; its role in tumorigenesis, drug resistance, and immune modulation; and its therapeutic potential in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.